Landsberg Bennett & Dubbaneh’s Novavax NVAX Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$370K	Buy	+2,039	New	+$449K	0.05%	202

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's NVAX Position: Q3 2021 in Review

Landsberg Bennett & Dubbaneh opened a new position in Novavax (NVAX) in Q3 2021: 2,039 shares worth $370K. The stake represents 0.05% of the portfolio and ranks #202 among its holdings.

443 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

Landsberg Bennett & Dubbaneh held 2,039 shares of Novavax worth $370K as of Q3 2021.
Novavax was a new Landsberg Bennett & Dubbaneh position in Q3 2021.
Novavax made up 0.05% of Landsberg Bennett & Dubbaneh's portfolio in Q3 2021, its #202 holding.
443 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q3 2021, filed 29 Oct 2021.